Ovarian Cancer Patient-Derived Organoids Used As a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study

Overview

Journal Cell Transplant

Specialties Cell Biology
General Surgery

Date 2024 Sep 26

PMID 39323050

Authors

Yu-Hsun Chang

Kun-Chi Wu

Kai-Hung Wang

Dah-Ching Ding

Affiliations

Soon will be listed here.

Abstract

This study aimed to explore the role of ovarian cancer patient-derived organoids (PDOs) in their replicating genetic characteristics and testing drug responsiveness. Ovarian cancer PDOs were cultured in Matrigel with a specialized medium. The successful rate and proliferation rate were calculated. Morphology, histology, and immunohistochemistry (IHC) (PAX8, P53, and WT1) were used to identify the tumor characteristics. Gene sequencing, variant allele frequency (VAF), and copy number variation were used to explore the mutation profile. The sensitivity to chemodrugs (carboplatin, paclitaxel, gemcitabine, doxorubicin, and olaparib) was conducted. Successful generation of organoids occurred in 54% (7/13) of attempts, encompassing 4 high-grade serous carcinomas (HGSC), 1 mucinous carcinoma (MC), 1 clear cell carcinoma (CCC), and 1 carcinosarcoma. The experiments used six organoids (3 HGSC, 1 CCC, 1 MC, and 1 carcinosarcoma). The derived organoids exhibited spherical-like morphology, and the diameter ranged from 100 to 500 μm. The histology and IHC exhibited the same between organoids and primary tumors. After cryopreservation, the organoid's growth rate was slower than the primary culture (14 days vs 10 days, < 0.01). Targeted sequencing revealed shared DNA variants, including mutations in key genes, such as , , and . VAF was similar between primary tumors and organoids. The organoids maintained inherited most copy number alterations. Drug sensitivity testing revealed varying responses, with carcinosarcoma organoids showing higher sensitivity to paclitaxel and gemcitabine than HGSC organoids. Our preliminary results showed that ovarian cancer PDOs could be successfully derived and histology, mutations, and diverse copy numbers of genotypes could be faithfully captured. Drug testing could reveal the individual PDO's responsiveness to drugs. PDOs might be as valuable resources for investigating genomic biomarkers for personalized treatment.

Citing Articles

Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions.

Hong M, Ding D Diagnostics (Basel). 2025; 15(4).

PMID: 40002556 PMC: 11854769. DOI: 10.3390/diagnostics15040406.

References

Maru Y, Tanaka N, Itami M, Hippo Y . Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. Gynecol Oncol. 2019; 154(1):189-198. DOI: 10.1016/j.ygyno.2019.05.005. View

Timmermans M, Sonke G, Van de Vijver K, van der Aa M, Kruitwagen R . No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer. 2017; 88:31-37. DOI: 10.1016/j.ejca.2017.10.030. View

Nanki Y, Chiyoda T, Hirasawa A, Ookubo A, Itoh M, Ueno M . Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Sci Rep. 2020; 10(1):12581. PMC: 7387538. DOI: 10.1038/s41598-020-69488-9. View

Senkowski W, Gall-Mas L, Marin Falco M, Li Y, Lavikka K, Kriegbaum M . A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. Dev Cell. 2023; 58(12):1106-1121.e7. PMC: 10281085. DOI: 10.1016/j.devcel.2023.04.012. View

Maenhoudt N, Defraye C, Boretto M, Jan Z, Heremans R, Boeckx B . Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models. Stem Cell Reports. 2020; 14(4):717-729. PMC: 7160357. DOI: 10.1016/j.stemcr.2020.03.004. View

Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G . Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics. 2011; 28(3):423-5. PMC: 3268243. DOI: 10.1093/bioinformatics/btr670. View

Vias M, Morrill Gavarro L, Sauer C, Sanders D, Piskorz A, Couturier D . High-grade serous ovarian carcinoma organoids as models of chromosomal instability. Elife. 2023; 12. PMC: 10174694. DOI: 10.7554/eLife.83867. View

Narod S . Can advanced-stage ovarian cancer be cured?. Nat Rev Clin Oncol. 2016; 13(4):255-61. DOI: 10.1038/nrclinonc.2015.224. View

Yang J, Huang S, Cheng S, Jin Y, Zhang N, Wang Y . Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current Opportunities. Front Cell Dev Biol. 2021; 9:701429. PMC: 8366314. DOI: 10.3389/fcell.2021.701429. View

10.

Pignata S, Cecere S, Bois A, Harter P, Heitz F . Treatment of recurrent ovarian cancer. Ann Oncol. 2017; 28(suppl_8):viii51-viii56. DOI: 10.1093/annonc/mdx441. View

11.

Ciccolini J, Serdjebi C, Peters G, Giovannetti E . Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016; 78(1):1-12. PMC: 4921117. DOI: 10.1007/s00280-016-3003-0. View

12.

Wu N, Fang C, Huang H, Wang J, Chu T . Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. Mod Pathol. 2019; 33(1):29-37. DOI: 10.1038/s41379-019-0370-1. View

13.

Li H, Durbin R . Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010; 26(5):589-95. PMC: 2828108. DOI: 10.1093/bioinformatics/btp698. View

14.

Koshiyama M, Matsumura N, Konishi I . Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014; 2014:934261. PMC: 4017729. DOI: 10.1155/2014/934261. View

15.

Yee C, Dickson K, Muntasir M, Ma Y, Marsh D . Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine. Front Bioeng Biotechnol. 2022; 10:836984. PMC: 8866972. DOI: 10.3389/fbioe.2022.836984. View

16.

McLaren W, Gil L, Hunt S, Riat H, Ritchie G, Thormann A . The Ensembl Variant Effect Predictor. Genome Biol. 2016; 17(1):122. PMC: 4893825. DOI: 10.1186/s13059-016-0974-4. View

17.

Cao Q, Li L, Zhao Y, Wang C, Shi Y, Tao X . PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway. Cell Transplant. 2023; 32:9636897231187996. PMC: 10369085. DOI: 10.1177/09636897231187996. View

18.

Wang K, Li M, Hakonarson H . ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164. PMC: 2938201. DOI: 10.1093/nar/gkq603. View

19.

Talevich E, Shain A, Botton T, Bastian B . CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol. 2016; 12(4):e1004873. PMC: 4839673. DOI: 10.1371/journal.pcbi.1004873. View

20.

Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Kallberg M . Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2015; 32(8):1220-2. DOI: 10.1093/bioinformatics/btv710. View